Related Experiment Video
Updated: Jun 27, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
Published on: April 19, 2013
Impact of FTO Genetic Variants on Colorectal Cancer Risk: A Case-Control Study
Zimo Yan1, Xianlei Zhou2, Wenlong Wu1
1College of Life Sciences, North China University of Science and Technology, Tangshan, China.
None:
This study aimed to assess the association between fat mass and obesity-associated (FTO) genetic variants and colorectal cancer (CRC) risk in a retrospective case-control cohort. FTO expression in CRC versus normal tissues was analyzed via UALCAN (TCGA), and the regulatory effects of rs9930506 and rs9940128 were assessed using GTEx data. A retrospective analysis was conducted on 870 CRC cases and 870 matched controls. Genotyping was performed using PCR-RFLP. Association with CRC risk was assessed by unconditional logistic regression with odds ratio (OR) and 95% confidence interval (CI), adjusted for age, sex, smoking status, and drinking status. Bioinformatics analysis revealed elevated FTO expression in colon cancer (p = 0.043), but not in rectal cancer (p = 0.250). Its variants rs9930506 and rs9940128 showed regulatory effects on gene expression in skeletal muscle and esophagogastric junction (p < 0.001). The FTO variant rs9930506 A > G was significantly associated with reduced CRC risk across multiple genetic models (GG vs. AA: OR = 0.30, 95% CI = 0.16-0.56, p < 0.001; AG+GG vs. AA: OR = 0.76, 95% CI = 0.62-0.93, p = 0.007; GG vs. AG+AA: OR = 0.32, 95% CI = 0.17-0.59, p < 0.001). These protective associations were preserved in non-smokers (all p < 0.05) and non-drinkers (all p < 0.01). In contrast, rs9940128 showed no significant association with CRC risk in any genetic model or stratum (all p > 0.05). The FTO rs9930506 polymorphism is associated with reduced CRC risk in this population, suggesting its role as a potential susceptibility marker.
Related Concept Videos
Cancer Prevention
Some...
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets

